Organic compounds -- part of the class 532-570 series – Organic compounds – Radioactive metal containing
Patent
1995-06-07
2000-08-01
Hollinden, Gary E.
Organic compounds -- part of the class 532-570 series
Organic compounds
Radioactive metal containing
534 14, 534 15, 534 16, 564316, 564319, C07F 1300, C07F 500, C07C21100, C07C22100
Patent
active
060968745
ABSTRACT:
The synthesis of tamoxifen derivatives, most particularly halo, halo alkyl, hydroxy, and amino tamoxifen derivatives is disclosed. The native tamoxifen molecule includes a substituted chemical group positioned on the aliphatic chain of the tamoxifen molecule. Particular tamoxifen derivatives of the invention include chloro, bromo, iodo, fluoro, amino and DTPA tamoxifen derivatives, and corresponding lower alkyl halogenated forms. The halogenated tamoxifen derivatives possess superior binding affinities for estrogen receptor rich tissues, such as uterine tissue and breast tissue, relative to unsubstituted native tamoxifen. Radiolabeled forms of the tamoxifen derivatives may be used as highly specific imaging agents for estrogen receptor rich tissues. The fluoro and bromo tamoxifen derivatives are particularly useful for imaging estrogen receptors by PET whereas the iodinated tamoxifens are particularly useful in imaging estrogen receptors by SPECT. Rapid and efficient methods of preparing the tamoxifen derivatives having high specific activity (>6 Ci/.mu.mol) are also disclosed. Aliphatic chain substituted tamoxifen derivatives are shown to possess greater estrogen receptor binding affinity and more potent tumor cell inhibition than tamoxifen or tamoxifen derivatives substituted at other locations on the molecule (i.e., non-aliphatic chain substituted tamoxifen). The tanioxifen derivatives of the present invention may advantageously be used as anti-cancer therapeutic agents to halt estrogen-receptor positive tumors, such as those of breast and uterine tissue. The present invention also provides a hydrophilic DTPA-tamnoxifen analogue, and uses thereof in imaging estrogen receptor positive ER+ lesions.
REFERENCES:
patent: 3288806 (1966-11-01), De Wald et al.
patent: 4696949 (1987-09-01), Toivola et al.
patent: 4806685 (1989-02-01), Abraham et al.
patent: 4839155 (1989-06-01), McCague
patent: 5192525 (1993-03-01), Yang et al.
patent: 5219548 (1993-06-01), Yang et al.
PCT Search Report mailed Sep. 12, 1996.
Allen et al., "Evidence for the Metabolic Activation of Non-Steroidal Antioestrogens: A Study of Structure-Activity relationships", J. Pharmac, 71:83-91, 1980.
Bezwoda et al., "The Value of Estrogen and Progesterone Receptor Determinations in Advanced Breast Cancer", Cancer, 68:867-872, 1991.
Fernandez et al., "Activated Oestrogen Receptors in Breast Cancer and Response to Endocrine Therapy", 20(1):41-46, 1984.
Hamacher et al., "Efficient Stereospecific Synthesis of No-Carrier-Added 2-[.sup.18 F]-Fluoro-2-Deoxy-D-Glucose Using Aminopolyther Supported Nucleophilic Substitution", J. Nucl Med, 27:235-238, 1986.
"Iodine-125-Labeled Estradiol: A Gamma-Emitting Analog of Estradiol that Binds to the Estrogen Receptor", Science, 205:1138-1140, 1979.
Kiesewetter et al., Preparation of Four Fluorine-18-Labeled Estrogens and Their Selective Uptakes in Target Tissues of Immature Rats, The Journal of Nuclear Medicine, 25(11):1212-1221, 1984.
Lien et al., "Distribution of Tamoxifen and its Metabolites in Rat and Human Tissues during Steady-State Treatment", Cancer Research, 51:4837-4844, 1991.
McCague et al., "Nonisomerizable Analogues of (Z)- and (E)-4-Hydroxytamoxifen. Synthesis abd Endocrinological Properties of Substituted Diphenylbenzocycloheptenes", J. Med. Chem, 31:1285-1290, 1988.
McElvany et al., "16.alpha.-[.sup.77 Br]Bromoestradiol: Dosimetry and Preliminary Clinical Studies", J Nucl Med, 23:425-430, 1982.
McGuire et al., "Positron Tomographic Assessment of 16.alpha.-[.sup.18 F] Fluoro-17.beta.-Estradiol Uptake in Metastatic Breast Carcinoma", J. Nucl Med, 32(8):1526-1531, Aug. 1991.
Mosmann, Tim, "Rapid Colorimetric Assay for Cellular Growth and Survival: Applications to Proliferation and Cytotoxicity Assays", Journal of Immunological Methods, 65:55-63, 1983.
Pollack et al., "Effect of Tamoxifen on DNA Synthesis and Proliferation of Human Malignant Glioma Lines in Vitro", Cancer Research, 50:7134-7138, Nov. 1990.
Salituro et al., "Iododesethyl Tamoxifen Aziridine: Synthesis and Covalent Labeling of the Estrogen Receptor with an Iodine-Labeled Affinity Label", Steroids, 48(5-6):287-313.
Schneider et al., "1,1,2-Triphenylbut-1-enes: Relationship between Structure, Estradiol Receptor Affinity, and Mammary Tumor Inhibiting Properties", J. Med. Chem., 25:1070-1077, 1982.
Tsai et al., "Antagonism of Development and Growth of 7,12-Dimethylbenz(a) anthracene-induced Rat Mammary Tumors by the Antiestrogen U 23,469 and Effects on Estrogen and Progesterone Receptors", Cancer Research, 27:1537-1543, 1977.
Wiseman et al., "Tamoxifen Inhibits Lipid Peroxidation in Cardiac Microsomes: Comparison with Liver Microsomes and Potential Relevance to the Cardiovascular Benefits Associated with Cancer Prevention and Treatment by Tamoxifen", Biochemical Pharmacology, 45(9):1851-1855, 1993.
Wiseman et al., "Protective Actions of Tamoxifen and 4-hydroxytamoxifen Against Oxidative Damage to Hman Low-Density Lipoproteins: A Mechanism Accounting for the Cardioprotective Action of Tamoxifen", Biochem J., 292:35-638, 1993.
Yang et al., "Halogenated Analogues of Tamoxifen: Synthesis, Receptor Assay, and Inhibition of MCF7 Cells", Journal of Pharmaceutical Sciences, 81(7):622-625, Jul. 1992.
Yang et al., "Imaging, Biodistribution and Therapy Potential of Halogenated Tamoxifen Analogues", Life Sciences, 55(1):53-67, 1994.
Hanson et al. (1982), Int. J. Nucl. Med. Biol., 9:105-107.
Loser et al. (1985), Eur. J. Cancer Clin. Oncol., 21(8):985-990.
Yang et al. (Jun. 11, 1991), The Society of Nuclear Medicine 38th Annual Meeting Cincinnati Convention Center, No. 12071.
Tansey et al. (Jun. 11, 1991), The Society of Nuclear Medicine 38th Annual Meeting Cincinnati Convention Center, No. 32680.
Yang et al. (Jun. 30, 1992) International Conference on Long- Term Antihormonal Therapy for Breast Cancer.
Foster et al. (1986) Anti-Cancer Drug Design, 1:245-257.
Francesco et al. (1986) Steroids, 48(5-6):287-313.
International Search Report (1992).
Watanabe et al. (1989) Journal of Chromatography, 497:169-180.
D'Argy et al. (1989) Chemical Abstracts, 110(3):259, Abstract No. 20581h.
Kangus et al. (1989) Chemical Abstracts, 110(25):10, Abstract No. 224948t.
Hannu et al. (1990) Chemical Abstracts, 113(17):Abstract No. 144793k.
DeGregorio et al (1987), Cancer Chemother Pharmacol 20:316-381.
Kallio et al (1986), Cancer Chemother Pharmacol 17:103-108.
Robertson et al (1982), J. Org. Chem. 47:2387-2393.
Katzenellenbogen et al (1984), Cancer Research 44:112-119.
Kuroda, et al (1985), J. Med. Chem 28:1497-1503.
Ram et al (1989), Journal of Labelled Compounds and Radiopharmaceuticals, 27(6):661-668.
Pomper et al (1988), J. Med Chem., 31:1360-1363.
Armstrong (1987), Journal of Chromatography, 414:492-196.
Lien et al (1987), Clin. Chem. 33(9):1608-1614.
Yang et al (1991), Pharmaceutical Research, 8(2):174-177.
Shani et al (1979), Cancer Treat Rep. (USA), 63 (7):Abstract No. 366.
Shani et al (1985), Med. Chem. 28:1504-1511.
Mintun et al (1988), Radiology, 169:45-48.
Foster et al (1985), J. Med. Chem. 28 (10):1491-1497.
Kangas et al (1986), Cancer Chemother Pharmacol 17:109-113.
DeGregorio et al (1989), Cancer Chemother Pharmacol 23:68-70.
Cherif A.
Delpassand E.
Quadri S.
Wallace Sidney
Yang David
Board of Regents , The University of Texas System
Hollinden Gary E.
Kelley Lara C.
LandOfFree
High affinity tamoxifen derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with High affinity tamoxifen derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and High affinity tamoxifen derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-665154